We recently announced 3 new RNA-based Archer FusionPlex® assays to detect fusions, point mutations and expression levels in genes implicated in hematological malignancies. The targeted NGS assays are powered by AMP enrichment chemistry, meaning that fusions can be identified in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints. Additionally, select genes are targeted for molecular barcode-enabled relative expression level detection and key point mutation coverage.
2477 55th Street, Suite 202
Boulder, CO 80301